Pulmonary drug and gene delivery to the lung represents a non-invasive avenue for local
and systemic therapies. However, the respiratory tract provides substantial barriers that …

Acute viral respiratory tract infections (AVRIs) are a major burden on human health and
global economy and amongst the top five causes of death worldwide resulting in an …

Colistin is an old antibiotic that has recently gained a considerable renewal of interest for the
treatment of pulmonary infections due to multidrug-resistant Gram-negative bacteria …

Engineered nanoparticles have the potential to expand the breadth of pulmonary
therapeutics, especially as respiratory vaccines. Notably, cationic nanoparticles have been …

Prothionamide (PTH), a second line antitubercular drug is used to administer in
conventional oral route. However, its unpredictable absorption and frequent administration …

Drug development is a critical step in the development pipeline of pharmaceutical industry,
commonly performed in traditional cell culture and animal models. Though, those models …

In recent years significant progress has been made to improve particle deposition in the
lung. However, the development of strategies to overcome the air–blood lung barrier is still …

In the past decade RNA-based therapies such as small interfering RNA (siRNA) and
messenger RNA (mRNA) have emerged as new and ground-breaking therapeutic agents for …

This review provides a brief overview of the variety of carriers employed for targeted drug
delivery used in cancer therapy and summarizes advantages and disadvantages of each …

Importance of the field: Since the 1950s, ultrasonic nebulizers have played an important role
in pulmonary drug delivery. As the process in which aerosol droplets are generated is …